Generic Name: sipuleucel-T

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Immunotherapy Medications

Company: Dendreon

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).

General Info

The Provenge vaccine works by removing a sample of dendritic cells (a type of immune cell that presents antigens to T cells), exposing them to a common prostate tumor antigen in a lab and returning them to the patient. The modified cells are then better able to recognize and attack prostate cancer.

Clinical trials showed that Provenge slows progression of prostate cancer and prolongs survival by about five months.


Dosing Info:

Provenge involves three intravenous infusions of modified T cells given about two weeks apart. The turnaround time from cell collection to reinfusion of the modified cells is usually around three days.

Side Effects

Common side effects include fatigue, chills, fever, nausea, back pain, joint pain and headache.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 18, 2018